Passarelli A L, Kovacs G R, Moss B
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
J Virol. 1996 Jul;70(7):4444-50. doi: 10.1128/JVI.70.7.4444-4450.1996.
Evidence is presented that a 26-kDa protein encoded by the vaccinia virus A2L open reading frame, originally shown to be one of three intermediate-stage genes that together can transactivate late-stage gene expression in transfection assays (J. G. Keck, C. J. Baldick, and B. Moss, Cell 61:801-809, 1990), is required for in vitro transcription of a template with a late promoter. The critical step in this analysis was the preparation of an extract containing all the required factors except for the A2L protein. This extract was prepared from cells infected with a recombinant vaccinia virus expressing the bacteriophage T7 RNA polymerase in the presence of the DNA synthesis inhibitor cytosine arabinoside and transfected with plasmids containing the two other known transactivator genes, A1L and G8R, under T7 promoter control. Reaction mixtures made with extracts of these cells had background levels of late transcription activity, unless they were supplemented with extracts of cells transfected with the A2L gene. Active transcription mixtures were also made by mixing extracts from three sets of cells, each transfected with a gene (A1L, A2L, or G8R) encoding a separate factor, indicating the absence of any requirement for their coexpression. To minimize the possibility that the A2L protein functions indirectly by activating another viral or cellular protein, this gene was expressed in insect cells by using a baculovirus vector. The partially purified recombinant protein complemented the activity of A2L-deficient cell extracts. Recombinant A1L, A2L, and G8R proteins, all produced in insect cells, together complemented extracts from mammalian cells containing only viral early proteins, concordant with previous in vivo transfection data.
有证据表明,痘苗病毒A2L开放阅读框编码的一种26 kDa蛋白是体外转录具有晚期启动子模板所必需的。该蛋白最初被证明是三个中期基因之一,在转染试验中,这三个基因共同可反式激活晚期基因表达(J.G.凯克、C.J.鲍迪克和B.莫斯,《细胞》61:801 - 809,1990)。该分析的关键步骤是制备一种提取物,其中除了A2L蛋白外包含所有必需因子。这种提取物是从感染了在DNA合成抑制剂阿糖胞苷存在下表达噬菌体T7 RNA聚合酶的重组痘苗病毒的细胞中制备的,并在T7启动子控制下用含有另外两个已知反式激活基因A1L和G8R的质粒进行转染。用这些细胞的提取物制成的反应混合物具有晚期转录活性的背景水平,除非用转染了A2L基因的细胞提取物进行补充。通过混合来自三组细胞的提取物也制成了活性转录混合物,每组细胞分别转染了编码一个单独因子的基因(A1L、A2L或G8R),这表明不需要它们共表达。为了尽量减少A2L蛋白通过激活另一种病毒或细胞蛋白间接发挥作用的可能性,该基因通过杆状病毒载体在昆虫细胞中表达。部分纯化的重组蛋白补充了缺乏A2L的细胞提取物的活性。在昆虫细胞中产生的重组A1L、A2L和G8R蛋白共同补充了仅含有病毒早期蛋白的哺乳动物细胞提取物的活性,这与之前的体内转染数据一致。